Blinatumomab

Cytokine Release Syndrome and Neurological Toxicities

  • Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO. Interrupt or discontinue BLINCYTO as recommended.[See Dosage and Administration (2.3), Warnings and Precautions (5.1)].
  • Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO. Interrupt or discontinue BLINCYTO as recommended. [See Dosage and Administration (2.3), Warnings and Precautions (5.2)

Patient counseling

REMS

Blincyto (blinatumomab) Injection

Medical guidelines

Patient Medication Guide

Package inserts

Blinatumomab

Updated: January 2018